KIERUNKI BADAWCZE - 2010 1. Uzależnienia lekowe środki psychostymulujące ce opioidy 2. Leki psychotropowe leki przeciwdepresyjne neuroleptyki anksjolityki 3. Ligandy metabotropowych receptorów glutamatergicznych efekty przeciwlękowe efekty przeciwparkinsonowe 4. Neuropeptydy /endomorfiny, NPY/ 5. Neuronalne mechanizmy choroby Parkinsona 6. Endogenne neurotoksyny /tetrahydroizochinoliny/ 7. Neuroprotekcja 8. Ból 9. Synteza ligandów w receptorów w 5-HT 5 i mglur struktura a działania ania biologiczne 10. Badania fitochemiczne
ZATRUDNIENIE (etaty) 2010 Średnioroczne 31.12.2007 Ogółem 172 179 Netto 168 173 STRUKTURA ZATRUDNIENIA 31.12.2007 1. Pion naukowy 131 (73%) Profesorowie i docenci 21 Adiunkci 31 Asystenci 27 Pracownicy inż.-techn. 47 Inni - POIG 65 2. Administracja i obsługa 48 (27%) Razem: 179 (100%)
Lata 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 PUBLIKACJE ORGINALNE Sumaryczny IF 200983 264,5 83 2009 2008 93 265,5 84 93 79 85 86 95 93 90 89 67 88 194,5 238,5 174,5 169,1 146,6 0 20 40 60 80 100 Liczba publikacji orginalnych
Liczba cytowań wg pierwszego autora (pominięto autocytacje) 1800 1400 1200 1000 800 600 INDEKS CYTOWAŃ 1600 1464 692 669 972 737 1164 935 1391 1300 1264 1429 1464 1996 1998 2000 2002 2004 2006 2008 Lata 1814 1892 2009
PUBLIKACJE IMPACT FACTOR punkty MNiSW 100 20 24 Liczba publikacji 80 60 40 20 0 2; 0.69% 5; 2.80% 55; 50.57% 17; 22.14% 5; 8.47% 2; 4.56% 1; 2.82% 1; 3.27% 1; 3.53% 0 1 2 3 4 5 6 7 8 9 10 Klasy co 1 punkt impaktowy
NAKŁADY ADY NA BADANIA - 2010 Kwota Koszty bezpośrednie badań w zakładach adach Sieci naukowe ( bez placówek obcych) Granty ( k-ty k bezpośrednie ) Umowy ( k-ty k pośrednie ) Projekt z funduszy strukturalnych POIG Razem: 757 538 809 919 2 958 110 269 377 5 000 000 10 983 120
NEUROPSYCHOFARMAKOLOGIA NEUROBIOLOGIA MODELOWANIE CHORÓB MÓZGU Interakcje molekuł Geny Wewnątrz komórkowe ścieżki przekazu sygnału Komórki nerwowe Systemy neuronalne Zachowanie
Department of Behavioral Neuroscience & Drug Development behavioral neuroscience and pharmacology of: drug addiction and dependence; anxiety; depression; learning and memory; pharmacology of ionotropic and metabotropic glutamate, nicotinic, serotonin receptor ligands.
Department of Brain Biochemistry DEPRESSION effects of antidepressants on expression of various alpha 1 -adrenoceptor subtypes; changes in the immune system induced by antidepressant treatments; G protein expression in animal models of depression. ADDICTION molecular correlates of drug dependence; neurochemical and molecular mechanisms of action of potential addictive and antiaddictive drugs; G protein expression in animal models of addiction.
Department of Experimental Neuroendocrinology effects of antidepressant and antipsychotic drugs on endocrinological and immunological systems; effects of antidepressants on the immune response; estrogen interactions with internal and external apoptotic pathways; modulators (SERMs) on excitatory amino acid-, proinflammatory cytokine-,, and dioxin-induced induced neuronal cell damage; intracellular mechanisms of apoptotic processes in neuronal cells; molecular interaction of antidepressants and drugs of abuse with corticosteroid receptors; excitotoxicity, seizures and apoptosis;
Department of Medicinal Chemistry structure-activity relationship (SAR) of centrally acting agents; computer-aided drug design; design and search for new antidepressant and anxiolytic agents; G-protein-coupled receptors; molecular mechanism of ligand-receptor interactions; molecular modelling; heterocyclic chemistry; stereochemistry and conformational analysis of organic compounds.
Department of Molecular Neuropharmacology The role of endogenous opioid peptides in physiology and pathology of the central nervous system; The molecular mechanism of drug tolerance and dependence Search for genes regulated by psychoactive drugs in the nervous system; An analysis of adaptive changes in the expression of genes induced by chronic treatment with drugs of abuse; Gene silencing using RNA interference (SiRNA); brain transcriptional gene networks and co-expression.
Department of Neurobiology Studies on central effects of stimulation/antagonism of metabotropic glutamate receptors; Studies on the mechanism of action of antidepressant drugs at the receptor and postreceptor level, including second messengers and protein kinases; Interaction between NPY or CRF and catecholamines or excitatory amino acids in the cortex, amygdala or hippocampus; The role of interaction between metal ions (Zn, Mg) and neurotransmission in the pathophysiology and treatment of affective disorders (animal and human studies).
Department of Neurochemistry PARKINSON'S DISEASE Animal models of PD addiction Behavioral and neurochemical correlates of craving and drug dependence
Department of Neuro- and Psychopharmacology Role of central dopaminergic, glutamatergic, GABAergic, serotonergic and adenosine receptors in Parkinson s s disease - animal models of progression of the diseases and its symptoms; The neurotoxic effects of substances which may be responsible for Parkinson s s disease; The role of nitric oxide in models of Parkinson's disease; neurobiological mechanisms underlying depression in Parkinson's disease.
Department of Pharmacokinetics and Drug Metabolism Contribution of brain cytochromes P450 to the local metabolism of o monoaminergic neurotransmitters and psychoactive drugs; role of the central nervous system in the regulation of cytochrome P450 expression; Interaction between psychotropic drugs and cytochrome P450 isoenzymes in the brain and liver; Identification and quantitative contribution of liver cytochrome P450 isoenzymes to the metabolism of centrally active drugs; pharmacokinetic interactions within clinical combinations of psychotropics; Mechanisms of pharmacokinetic interactions; pharmacokinetics and metabolism of psychotropic drugs after acute and chronic treatment;
Department of Pharmacology Psychopharmacology and psychobiology of depression, psychosis, anxiety and addiction; Mechanism of action of antidepressant drugs; studies designed to identify novel, potential antidepressant Antipsychotic drugs in neurodevelopmental animal models of schizophrenia; The serotonin system and anxiolytic activity; Proliferation of neurons in adult hippocampus, behavioral symptoms related to the development of drug addiction; The impact of environmental and pharmacological agents on brain development.
Department of Pharmacology of Pain The role of endogenous opioid peptides in physiology and pathology of the central and peripheral nervous system; The role of cannabinoids and endowanilloids in physiology and pathology of the central nervous system; Investigation of new drugs in acute and chronic pain animals models; search of new pain therapy; Pharmacological and biochemical analysis of neuroimmune interactions in acute and chronic nociceptive processes.
Department of Physiology Adaptive modification in the responsiveness of hippocampal and frontal cortical neurons to 5-hydroxytryptamine induced by repeated treatment with psychotropic drugs and corticosterone; Adaptive modifications of glutamatergic transmission in the frontal cortex induced by antidepressant treatments and corticosterone; The significance of prostaglandins (PG) generated by constitutive and inducible cyclooxygenase in the corticotropin releasing hormone (CRH) and vasopressin (AVP)-induced activity of the hypothalamicpituitary-adrenocortical (HPA) axis during chronic social stress; The role of neurotransmitters in the central regulation of the HPA under basal and stress conditions.
www. if-pan.krakow.pl